Dr. Angela Smith discusses FDA approval of Jelmyto for low-grade UTUC

This is episode's guest is Dr. Angela B. Smith, Co-director of the Multidisciplinary Genitourinary Oncology Service at the N.C. Cancer Hospital; Director of Urologic Oncology in the UNC Department of Urology; and Associate Professor of Urology at UNC School of Medicine. A member of the study advisory committee for UroGen Pharma, Smith discusses the recent FDA approval of Jelmyto, which is the first therapy for the treatment of low-grade upper tract urothelial cancer.